Ochratoxins in Wines: A Review of Their Occurrence in the Last Decade, Toxicity, and Exposure Risk in Humans

Bryan Ortiz-Villeda, Olga Lobos, Kateryn Aguilar-Zuniga and Verónica Carrasco-Sánchez *

Abstract: Ochratoxins (OTs) are mycotoxins frequently found in wines, and their contamination can occur during any stage of the winemaking process. Ochratoxin A (OTA) has been the most widely reported and the only one whose concentrations are legislated in this beverage. However, ochratoxin B, ochratoxin A methyl ester, ochratoxin B methyl ester, ochratoxin A ethyl ester, ochratoxin B ethyl ester, ochratoxin α, ochratoxin β, OTA methyl ester, OTA ethyl amide, and OTA glucose ester have also been reported in wines. Thus, detecting only OTA would lead to the underestimation of ochratoxin levels, which is a risk to human health. Considering the threat represented by the presence of ochratoxins in wines and the long-term health problems that they can cause in wine drinkers, this paper aims to review reports of the last 10 years regarding the presence of different ochratoxins in wines and how the winemaking process influences the degree of contamination, mainly by OTA. Additionally, toxicity from human exposure due to the consumption of contaminated wines is addressed.

Keywords: mycotoxins; ochratoxins; wines

Key Contribution: Worldwide, wines are contaminated with different types of ochratoxins; therefore, the risk of exposure from the consumption of contaminated wines is underestimated when only evaluating ochratoxin A.

1. Introduction

Ochratoxins (OTs) are a group of mycotoxins produced by different *Penicillium* and *Aspergillus* molds that contaminate crops in the field [1]. These toxins are derivatives of an isocoumarin moiety linked to phenylalanine by an amide bond (Figure 1) [2].

![Ochratoxin Structure](https://example.com/ochratoxin_structure.png)

**Figure 1.** Ochratoxins structure. The red color represents the phenylalanine moiety deriving from the shikimic acid pathway. The green color represents the isocoumarin nucleus. OTA: ochratoxin A; MeOTA: ochratoxin A methyl ester; OTC: ochratoxin C; OTB: ochratoxin B; MeOTB: ochratoxin B methyl ester; EtOTB: ochratoxin B ethyl ester, OTα, and OTβ.
In wines, OTA is the most studied mycotoxin, and the European Commission (by regulation 1881/2006) established as the maximum tolerable level in wines destined for human consumption a concentration of 2 µg kg⁻¹ [3]. OTA contamination can occur during any stage of the winemaking process. Contamination can be produced from the early stages of the colonization of mycotoxigenic fungi in grapes to the final steps in the wine packaging process. However, the primary contamination of the finished product comes from the carryover of mycotoxins from grapes [4,5]. In addition, the winemaking process strongly influences the OTA content, since higher concentrations have been reported in red wines than in rosé and white wines in general [6].

Ochratoxins other than OTA have been reported in wines [7], but because they present different polarity and solubility, their detection and quantification using conventional analytical methods becomes difficult, leading to underestimations of total mycotoxin levels [7,8]. So far, the other ochratoxins present in wines have been identified as ochratoxin B (OTB), ochratoxin A methyl ester (MeOTA), ochratoxin B methyl ester (MeOTB), ochratoxin A ethyl ester (OTC), ochratoxin B ethyl ester (EtOTB), ochratoxin α (OTα, an isocoumarin derivative of OTA) ochratoxin β (OTβ, a dechlorinated analog of OTα), OTα methyl ester, OTA ethyl amide, and OTA glucose ester [9–11]. Although they are not regulated in wine, their presence is undoubtedly a risk to human health.

The contamination of wines with ochratoxins should raise a tremendous public health alert worldwide for frequent drinkers, since these toxins can cause acute to chronic poisoning. The latter is associated with the cumulative effect of these toxins in various organs when they are ingested constantly over a long time and can cause the occurrence of chronic complications such as cancer, immunological alterations, nephropathies, neurotoxicity, and hepatotoxicity, among others [12].

The presence of OTA in wines has been reviewed by several authors [6,13,14]; however, most of these publications covered reports only until 2012. Considering the risk of contamination by ochratoxins and the long-term health problems they can cause, this review aims to analyze the presence of ochratoxins in wines reported in the last 10 years, explore how the winemaking process influences the degree of contamination, and examine the associated toxicity in terms of the risk of human exposure from the consumption of contaminated wines.

2. Occurrence of Ochratoxins in Wines

2.1. Ochratoxin A

OTA structurally consists of a p-chlorophenolic group linked to a dihydroisocoumarin fragment linked by an amide bond to an L-phenylalanine (Figure 1) [15].

According to some research, OTA contamination occurs when grapes are still on the vine, during the ripening period when fungal infections are more active [16,17]. Aspergillus carbonarius, A. ochraceus, A. niger, Penicillium verrucosum, and P. nordicum are the main fungal species responsible for producing this toxin in grapes [18], with Aspergillus species being more frequent [19]. The grape harvesting process is critical in terms of contamination with mycotoxigenic fungi, especially if there is a lack of cleanliness of the tools and containers used. Similarly, contamination of grapes can also occur during transport to the winery, during storage, or because of careless handling by staff, since the skin of these fruits is thin and can be easily injured, allowing colonization and development of mycotoxigenic fungal species [20].

In the crushing step, grapes are broken to extract the juice. When grapes contain OTA (in their pulp and/or skin), the toxin will be transferred to the must [6].

For red wines, the maceration process is then carried out. During this stage, there can be increased OTA content (about 20%) [21] because of the long contact between grape skins and must, which favors the solubility and diffusion of this mycotoxin from contaminated skins [22]. On the other hand, the absence of maceration for white and rosé wines seems to be a critical factor contributing to low OTA levels in these wines [14].
After maceration for red wines and crushing for white and rosé wines, alcoholic fermentation occurs, a process by which the sugars present in the grapes, thanks to the metabolism of yeasts, are converted into alcohol. Although mycotoxigenic fungi can accompany the grapes from the time they are on the vine, the fermentation process inhibits their growth [23]. It has even been shown that living spores of *A. carbonarius* isolated during alcoholic fermentation cannot produce OTA [24]. Along with this, at the end of the alcoholic fermentation process, OTA levels decrease by 35 to 70% [14].

OTA adsorption can be carried by yeast cell walls (composed of mannoproteins and β-glucans) [25]. It was shown that chitin, β-glucan, and their hydrolysates could remove 64 to 74% of OTA from contaminated wine [26]. A similar process occurs during malolactic fermentation, which involves lactic acid bacteria (LAB) [27]. Some authors have reported the ability of LABs to decrease OTA concentrations between 10 and 43% during the winemaking process [28]. OTA removal for LAB would be in the form of adsorption to cellular components such as exopolysaccharides and peptidoglycans [21,28].

A 54% reduction in OTA content has been seen in wines stored for 5 months [6], and OTA concentrations in red wine stored at room temperature for 55 days and 80 days showed decreases of 8 and 10%, respectively [29]. The OTA reduction in wine after storage and drainage is due to the precipitation of solid particles from the remains of pulp, skin, and yeast and dead bacteria, which form the lees [6]. This could be due to the wine sedimentation process, which contributes to further reduction of OTA content [13,30].

After clarification with gelatin in the macro-vinification process, there was evidence of a decrease in toxin content by around 58%. On the other hand, using a mixture of gelatin and bentonite, the concentration of OTA does not decrease significantly [6]. Other clarifying agents, such as oenological carbon and bentonite, have been shown to reduce the OTA concentration in wine [31,32]. However, the fining agent concentration, the chemical nature of the wine components, the OTA concentration, and the adsorption capacity of other elements present in the wine must be considered.

Finally, throughout the winemaking process, evidence shows that OTA levels can be decreased. Recently, a new scenario was raised, in which a third of the reduction may be related to the degradation of OTA or transformation into modified mycotoxins during the fermentation process [8].

The presence of OTA in wine was first reported in 1996 in Switzerland [33]. Since that first report, this mycotoxin has been described in different wines on several countries worldwide. Table 1 lists the wine reports from 2012. Among the reports that most attract attention is one in which 100 samples of wine produced in Portugal, Spain, and Italy were analyzed. The interesting thing about this study is that the year of production varied from 1984 to 2017, and interestingly, the contaminated samples were from wine made in recent years, two red wines in Portugal in 2016, one red wine in Lisbon in 2016, and one in Italy in 2015. The contaminated white wine that was sampled was produced in Italy in 2016 [34].

Another work that draws attention is a recent study that analyzed 113 bottled wines from the 2011 to 2016 vintages. Of the total wines evaluated, 64% of red wines had at least traces of OTA, while the percentages of white and rosé wines were considerably lower (42.6 and 36.4%, respectively). Regarding the harvest year, the occurrence of OTA varied markedly. The samples with the highest levels of contamination were from the 2014 and 2015 harvests (71.0 and 86.7%, respectively) [35].

It is essential to have these data because of the increased OTA in wines after 2014 [34,35], which, according to some researchers, may be due to the consequences of climate change.
Table 1. Studies of the occurrence of OTA in wines. Reports from 2012 to 2021.

| Sampling Location | Wines | Positive/Total Samples | OTA Range (µg L⁻¹) | Method | LOD | Ref. |
|-------------------|-------|-------------------------|--------------------|--------|-----|-----|
| Portugal Red, white | 5/100 | <LOD–1.2 HPLC-FLD | 0.08 [34] |
| Serbia Red, white, rose | 59/113 | <LOD–0.13 HPLC-FLD | 0.001 [35] |
| Spain Red | 51/51 | 0.0005–0.014 HPLC-FLD | 0.00032 [36] |
| Holland Red | 6/280 | 0.2–0.6 UPL-MS NR* | [37] |
| Czech Republic Red, white | 8/24 | 0.0–0.7 HPLC-FLD NR* | [38] |
| Italy Sweet | 29/30 | <LOD–1.6 HPLC-FLD | 0.01 [39] |
| Italy Red, white | 55/55 | 0.08–0.7 UPLC-FLD | 0.01 [40] |
| Poland - | 8/32 | 0.1–0.5 HPLC-FLD | 0.05 [41] |
| Portugal Red | 4/6 | <LOD–0.17 HPLC-FLD | 0.017 [42] |
| Croatia Red | 102/110 | <LOD–0.16 HPLC-FLD | 0.006 [43] |
| Greece - | 10/23 | 3.4–15.6 ELISA | 1.0 [44] |
| Chile Red, white | 34/1188 | <LOD–0.4 HPLC-FLD | 0.01 [45] |
| United States of America Red, white | 12/143 | 0.1–0.4 UHPLC-MS/MS | 0.1 [46] |
| United States of America - | 6/343 | <LOD–0.4 LC-MS/MS | 0.1 [47] |
| Argentina Red | 136/136 | <LOD–1 UHPLC-MS/MS | 0.02 [48] |
| United States of America Red, white, dry, sweet | 35/41 | 0.3–8.6 HPLC-FLD | 0.1 [49] |
| Paraguay Red | 1/4 | 2.4 ELISA | 2.0 [50] |
| Japan Red, white | 5/27 | <0.2–0.4 UHPLC-MS/MS | 0.06 [51] |
| China Red, white | 223/223 | <LOD–1 HPLC-FLD | 0.01 [52] |
| Thailand Red | 10/100 | 0.3–1.7 LC-MS/MS | 0.06 [53] |
| China - | 2/42 | 1.3 UHPLC-MS/MS | 0.1 [54] |
| Tunisia Red, white, rose | 29/34 | 0.1–1.5 HPLC-FLD | 0.03 [55] |
| Italy Red | 2/30 | 2.0 HPLC-FLD NR* | [56] |
| Italy Red | 41/57 | <LOD–0.7 HPLC-FLD | 0.02 [57] |
| Italy Red, and white | 37/58 | <LOD–0.3 HPLC-MS/MS | 0.012 [58] |
| Hungary Sweet wines (Tokaj) | 7/53 | <LOD–0.3 HPLC-FLD | 0.03 [59] |

2.2. Other Ochratoxins

The alcoholic and acidic nature of wine allows carboxylic acid transformation to an ethanolic ester in OTA [33]. Furthermore, the acidic conditions of the matrix may favor ionization of the amino group of the OTA molecule. Along with this, acids can favor esterification reactions (addition of methyl and ethyl groups). Furthermore, during the alcoholic fermentation process, the enzymes produced by the yeasts present can modify OTA. *Saccharomyces cerevisiae* has been shown to produce glucosidases, pectinases, and xylanases that can act on the hydrolysis of OTA [8].

The first report of co-occurrence of OTA with OTC in wines was in 1996, estimating that the OTC concentration was approximately 10% of the OTA concentration (Table 2) [33]. Subsequently, in 2010, it was reported that 100% of red wines purchased from Spain presented co-occurring OTA and OTB although at low levels, and none of them exceeded the maximum level of OTA permitted by legislation. Additionally, it was reported that 60% of the samples presented three ochratoxins (eight showed OTA, OTB, and OTC, and four, OTA, OTB, and MeOTA) [9].

OTA, OTB, MeOTA, MeOTB, OTC, and EtOTB were reported in 51 red wines from Spain, corroborating previously published data, with levels of OTA and OTB detected in all wines. Among the samples, 71% showed the presence of OTC, and in 18%, the six ochratoxins analyzed appeared simultaneously [36]. Another study reported that all wines obtained in the Mediterranean were contaminated with OTB, 89.6% with OTC, 62.5% with
MeOTA, 83.3% with MeOTB, and 83% with EtOTB. The co-occurrence of two mycotoxins in 100% and six ochratoxins in 44.8% of the samples was also found. It has been reported that the presence of OTC in wine is mainly due to the hydrolysis of OTA [60]. Therefore, ochratoxin intake from wine can be underestimated when only assessed by OTA analysis.

Table 2. Ochratoxin analogues studies in wines.

| Wines                        | Ochratoxin | Positive Wines | Range (µg L\(^{-1}\)) | Method    | LOD (µg L\(^{-1}\)) | Ref. |
|------------------------------|------------|----------------|------------------------|-----------|----------------------|------|
| Red wines; \(n = 20\)        | OTA        | 100%           | 0.001–0.1              | HPLC-FLD  | 0.00016              | [9]  |
|                             | OTB        | 100%           | 0.003–0.02             |           | 0.00032              |      |
|                             | MeOTA      | 50%            | <LOD–0.001             |           | 0.00027              |      |
|                             | OTC        | 70%            | <LOD–0.004             |           | 0.00017              |      |
| White, rose, and red wines;  | OTA        | 92.4%          | <LOD–0.4               | HPLC-FLD  | 0.003                | [33] |
| \(n = 133\)                  | OTC        | 10%            | -                      |           | NR *                 |      |
| Red wines; \(n = 51\)        | OTA        | 100%           | 0.001–0.01             | HPLC-FLD  | 0.00032              | [36] |
|                             | OTB        | 100%           | 0.003–0.1              |           | 0.00016              |      |
|                             | OTC        | 70.6%          | 0.0002–0.001           |           | 0.00017              |      |
|                             | MeOTA      | 41.2%          | 0.0002–0.004           |           | 0.00021              |      |
|                             | MeOTB      | 92.2%          | NR*–0.01               |           | NR *                 |      |
|                             | EtOTB      | 43.1%          | NR*–0.001              |           | NR *                 |      |
| Sweet wines; \(n = 30\)      | OTA        | 96.6%          | <LOD–1.6               | HPLC-FLD  | 0.01                 | [38] |
|                             | OTB        | 83.3%          | <LOD–1.2               |           | 0.02                 |      |
| Red wines; \(n = 96\)        | OTA        | 99%            | <LOD–0.5               | HPLC-FLD  | 0.00032              | [60] |
|                             | OTB        | 100%           | 0.002–0.1              |           | 0.00016              |      |
|                             | MeOTA      | 62.5%          | <LOD–0.1               |           | 0.00021              |      |
|                             | OTC        | 89.6%          | <LOD–0.03              |           | 0.00017              |      |

* NR: not reported.

3. Toxicity of Ochratoxins and Risk of Exposure through the Consumption of Contaminated Wine

3.1. OTA Toxicity and Biotransformation

For humans, the ingestion of mycotoxins constitutes a danger, as they have been linked to mutagenicity and to estrogenic, gastrointestinal, urogenital, renal, nervous, and immunosuppressive disorders [61]. Among their most alarming characteristics is their cumulative effect over time, representing a triggering factor in several types of cancer [62,63]. Of all the mycotoxins reported in wines, OTA is currently considered the most relevant. This molecule has been mainly associated with a nephrotoxic effect, as observed in Balkan endemic nephropathy (BEN), caused by the bioaccumulation of OTA in the renal parenchyma [64,65]. Other effects attributed to this mycotoxin are teratogenesis, immunotoxicity, genotoxicity, mutagenicity, and oncogenicity [65].

After being ingested, a minor fraction of OTA is absorbed in the stomach (due to the rapid chyme transit and the thickness of its mucous layer) [66–68]. Contrary to what happens in the small intestine, particularly between the duodenum and the jejunum, which is where more significant amounts of OTA are absorbed, because the evacuation of alimentary chyme is slow, the membranes in this anatomical area are more permeable, which facilitates the absorption of this mycotoxin [66,67]. Another variable that is strongly involved in absorption is the pH of this mycotoxin. The \(\text{pK}_a\) of OTA ranges from 4.2 to 4.4 (monoanionic form) and 7.2 to 7.4 (dianionic form); absorption of OTA, according to the physiological pH found in the stomach and small intestine (ranging from 1.5 to 2.5 and 6.1 to 7.8, respectively) occurs in its non-anionic and monoanionic forms [65]. It is important to note that when this mycotoxin is absorbed through the small intestine, it can affect the integrity of the walls, causing inflammation and intestinal disorders [68].

When the binding of OTA to albumin occurs, it is brought to different tissues [69]. OTA is metabolized very slowly in humans, with a half-life of more than 30 days [70,71], producing a cumulative effect leading to cell damage in different organs [71]. The main
3.3. Risk of Exposure to Ochratoxins through the Consumption of Contaminated Wines

It has been shown that OTC leads to various immunomodulatory effects in porcine monocytes [80]. Although not responsible for toxicity, OTC and OTA may be crucial for differential binding and uptake of ochratoxins [81]. It is assumed that the minor structural difference (chlorine in OTA versus hydrogen in OTC) results in a toxicity mechanism different from chronic toxicity compared to OTA. Furthermore, it can be assumed that both toxins can be equally absorbed and bound intracellularly, although several results suggest a molecular mechanism different from OTA oxidation, which is a compound with low toxicity, while another less toxic product is 10-hydroxyochratoxin A (10-OH-OTA) [66].

In the recent past, wine has been considered the second most important dietary source of OTA after cereals [85]. In women between 18 and 59 years of age, wine is a significant source of OTA consumption [38]. Currently, this represents a contribution of up to 5% of the total intake of this toxin in the elderly population [35].

Due to all of these contraindications, the International Agency for Research on Cancer (IARC) in 1993 classified OTA in group 2B as a possible carcinogen for humans, which means that there is some evidence that it can cause cancer in humans, but so far, it is not conclusive [72]. However, currently, it is considered that there should be a change in this classification, since investigations carried out with experimental animals during the last 20 years confirm that this mycotoxin is carcinogenic, nephrotoxic, and genotoxic and is also associated with gallbladder cancer due to the consumption of contaminated food [73].

When OTA is ingested, it can undergo biotransformations (Figure 2). OTA is hydrolyzed to OTα by the action of proteolytic enzymes and enzymes of bacterial microflora in the intestine. What makes hydrolysis of OTA possible is the opening of the lactone ring that under alkaline conditions results in forming a highly toxic compound called open OTA with lactone (OP-OTA). Likewise, 4-hydroxyochratoxin A (4-OH-OTA) is a product of OTA oxidation, which is a compound with low toxicity, while another less toxic product is 10-hydroxyochratoxin A (10-OH-OTA) [66].

Figure 2. Biotransformation associated with OTA.

In addition, the formation of other metabolites derived from the biotransformation of OTA has been observed in other species, such as OTB, and the result of the conjugation of OTA with compounds such as sulfate, glucuronide acid, hexose/pentose (hex/pent-OTA), and glutathione, among others. The production of these metabolites is essential to consider because they can interact with other molecules, leading to more toxic molecules. Ochratoxin C is a potentially toxic compound. It has been concluded that ochratoxin C is readily converted to ochratoxin A after either oral or intravenous administration [66,74].

It is also important to note that the total consumption of OTA in the daily diet depends on all the products ingested containing this mycotoxin. Exposure to OTA through food intake can be measured in biological fluids using mycotoxin biomarkers. The OTA concentration in blood is a well-known marker of constant exposure to this toxin due to its long half-life (~35 days) in the circulatory system [75]. In addition, measuring urinary mycotoxin biomarkers is an effective alternative to measuring exposure to mycotoxins, given that the excretion of biomarkers correlates well with mycotoxin intake [76]. In this regard, a human biomonitoring study performed on the Belgian population revealed that, among 33 mycotoxins analyzed, OTA was one of the most frequently detected in urine.
samples, indicating a high prevalence of OTA exposure in adults and children in this population associated with food consumption, suggesting the presence of urinary mycotoxin as a valuable biomarker for assessing OTA exposure [77].

3.2. Toxicity Associated with OTA Derivates

OTB is less toxic in vivo than OTA, attributed to a lower affinity for plasma proteins, no specific retention in the kidneys, and more extensive metabolization and faster excretion than OTA [78,79]. On the contrary, it has been shown that both toxins can be equally acutely cytotoxic in vitro in exposed LLC-PK1 cells [80], provided that similar amounts are absorbed and bound intracellularly, although several results suggest a molecular mechanism different from chronic toxicity compared to OTA. Furthermore, it can be assumed that the minor structural difference (chlorine in OTA versus hydrogen in OTB), although not responsible for toxicity, may be crucial for differential binding and uptake in cells [81].

OTC has similar acute toxicity in vivo and in vitro compared to OTA; however, it remains to be determined whether the mode of action of OTC and OTA is the same [80]. It has been shown that OTC leads to various immunomodulatory effects in porcine mononuclear cells [82] and the human monocyte/macrophage THP-1 line in concentrations between 10 and 1000 ng mL$^{-1}$ [80].

The derivative 4R-OH-OTA was shown to be equally cytotoxic compared to OTA in HTC cells. Furthermore, both OTA and 4R-OH-OTA inhibit protein synthesis, attributed to their binding on the phenylalanine sites of phenylalanyl-tRNA synthetase, and they possess similar toxic effects on the IgM and IgG response [81].

The derivative 10-OH OTA is non-genotoxic (DNA adduct formation) in bronchial epithelial cells (WI 126 VA) [83,84]. Based on some of the results above, hydroxylation of ochratoxins (particularly 4R-OH-OTA) does not affect their toxicity. In summary, based on the limited data from the above studies, no clear general toxicity ranking can be made; however, OTA seems to be overall the most toxic, followed by OTC, OTB, and OTα [81].

3.3. Risk of Exposure to Ochratoxins through the Consumption of Contaminated Wines

In the recent past, wine has been considered the second most important dietary source of OTA after cereals [85]. In women between 18 and 59 years of age, wine is a significant source of OTA consumption [38]. Currently, this represents a contribution of up to 5% of the total intake of this toxin in the elderly population [35].

The European Food Safety Authority (EFSA), based on the renal toxicity that can result from OTA, established a tolerable weekly intake (TWI) level of 120 ng kg$^{-1}$ body weight (bw), which corresponds to a tolerable daily intake (TDI) of 17 ng kg$^{-1}$ bw day$^{-1}$. According to data presented by EFSA, the estimated amount of OTA that an average person could ingest with the consumption of products such as cereals, wine, beer, grapefruit, coffee, pork, and cocoa over the course of a week varies from 15 to 20 ng kg$^{-1}$ bw day$^{-1}$, and in those who consume these foods very frequently, ingestion varies from 40 to 60 ng kg$^{-1}$ per bw week$^{-1}$ [86].

The estimated daily intake (EDI) of mycotoxins through wine consumption can be calculated using the average concentration of mycotoxins in the samples (µg L$^{-1}$), the average consumption of wine per day (L day$^{-1}$), and body weight (kg) [35,50,52]. The EDI of OTA in wines has been evaluated by several researchers, mainly on the European continent (Table 3), and the results so far are in the range of 0.0002 to 4.1 ng kg$^{-1}$ bw day$^{-1}$, indicating that consumption of this mycotoxin is relatively low, considering the TDI proposed by EFSA. It is also important to note that total exposure to OTA in the daily diet will depend on all products consumed that contain it.
Table 3. Estimated daily intake (EDI) of OTA for wine consumption.

| Country      | EDI (ng kg\(^{-1}\) bw day\(^{-1}\)) | Ref. |
|--------------|--------------------------------------|------|
| Switzerland  | 0.7                                  | [33] |
| Portugal     | 0.01                                 | [34] |
| Serbia       | 0.004                                | [35] |
| Spain        | 0.01                                 | [36] |
| Czech Republic | 0.01–0.03                            | [38] |
| Italy        | 4.1                                  | [40] |
| Poland       | 0.0002                               | [41] |
| USA          | 0.01                                 | [47] |
| China        | 0.1–0.2                              | [52] |
| Thailand     | 0.3                                  | [53] |
| Portugal     | 2.9–5.4                              | [87] |
| Spain        | 0.01                                 | [88] |
| France       | 2                                    | [89] |
| Greece       | 3.7                                  | [90] |
| Italy        | 0.9–1.4                              | [91] |

Risk assessment for OTA ingestion through contaminated wines has also been carried out by calculating the hazard quotient (HQ) [41,92] and margin of exposure (MOE) [79] values (Table 4).

Table 4. Parameters to determination of risk exposure to OTA due to the consumption of wines.

| Parameters | Interpretation of Results |
|------------|---------------------------|
| EDI <17 ng kg\(^{-1}\)bw day\(^{-1}\) | The estimated daily intake of OTA should never be greater than the tolerable daily intake that corresponds to 17 ng kg\(^{-1}\)bw day\(^{-1}\) |
| HQ <1 | Suggests that carcinogenic effects are unlikely |
| HQ >1 | Is indicative that the OTA present in the matrix are potential agents that cause adverse health effects |
| MOE ≥200 | Non-neoplastic effects |
| MOE ≥10,000 | Suggests neoplastic effects |

Note. EDI: estimated daily intake; HQ: hazard quotient; MOE: margin of exposure.

The hazard quotient, proposed by US Environmental Protection Agency (USEPA), is a tool used to calculate the carcinogenic risk of ingesting a compound that is harmful to health and can represent human exposure through the consumption of such compounds in food and beverages. The HQ of OTA is calculated by dividing the average daily dose (PDD) of mycotoxin in wine by the TDI [41].

The EFSA scientific committee has recommended using the MOE for the risk assessment of substances that are considered genotoxic and carcinogenic and may be present in food at low levels. Briefly, the MOE is a relationship of two factors that can be evaluated in a given population: the dose at which a small but measurable adverse effect is first observed and the level of exposure to a substance considered genotoxic or carcinogenic [86], which is calculated by dividing the lowest benchmark dose (BMDL) by the estimated mycotoxin intake, where BMDL10 represents the lower end of the benchmark dose, which indicates an increased risk of cancer by 10% over the control [93,94].
Based on the above, several authors have concluded that wine does not represent a danger to human health as a source of OTA [35,37,41,46,53,54]. Among the justifications for this approach, it is pointed out that despite the presence of OTA in wines, it may be possible that toxic levels of this mycotoxin are somehow offset by the beneficial effects of the derivatives of resveratrol. Additionally, the concentrations found in wine are minimal compared to those found in other food matrices, so the risk of exposure to this mycotoxin through wine consumption is minimal.

However, these pronouncements are not entirely truthful, as has become evident. Ochratoxin levels in wines may be underestimated, since most studies on the occurrence and risk of exposure were focused on OTA and not its derivatives. Therefore, the presence of other ochratoxins and the lack of concern about detecting them in wine represents a potential risk to human health.

The presence of these modified metabolites in wines could represent three possible scenarios: (1) a decrease in or elimination of toxicity occurs for the primary molecule [7,8]; (2) these compounds could be as toxic or more toxic than the original molecule due to their structural similarities [8,17]; or (3) when ingested in wine, through human metabolism, these molecules can be reconverted into the original toxin [95]. It should not be ruled out that synergism occurs between modified OTAs and free OTA or other molecules present in this matrix.

4. Conclusions

OTA is a mycotoxin widely studied in wines. The winemaking process is known to influence the presence and concentration of this toxin, since red wines are more contaminated than white and rosé wines. Evidence shows that OTA levels decrease throughout the winemaking process due to loss or degradation. This is a worrying aspect to consider, since the total ochratoxin levels may have been underestimated by not considering the OTA derivates.

OTA derivatives in wines are OTB, MeOTA, MeOTB, OTC, EtOTB, OTα, OTβ, OTα methyl ester, OTA ethyl amide, and OTA glucose ester of which there is little information on its toxicity. Although analogs analysis is essential, it is somewhat complex, since having different polarities and solubility, making their detection and quantification by conventional analytical methods difficult.

The few studies that analyze OTB in wines show that its prevalence is over 80% when OTA is 100%, with similar concentrations. As for OTC, its prevalence in wines ranges 70%, and its concentration is equivalent to 10% of OTA concentration.

TDI established by EPSA for OTA is 17 ng kg\(^{-1}\) bw day\(^{-1}\), and the maximum estimated range ofEDI in wines is 4.1 ng kg\(^{-1}\) bw day\(^{-1}\) in drinkers. The OTA intake through the consumption of contaminated wine corresponds ≈24% of the total daily quota. However, being considered OTB and OTC, it would be estimated that this percentage would exceed 40% of the tolerable daily intake. Although, OTB is less toxic than OTA, and OTC easily converts to OTA after oral administration. Therefore, the underestimation of these derivatives brings with it a worrying scenario for public health.

The underestimating ochratoxin concentration in wines is accurate, and future studies should focus on evaluating the exposure risk to total ochratoxins and not just OTA. Furthermore, it is essential to carry out a more profound toxicity analysis of OTA derivatives to investigate whether synergism or antagonism between the different ochratoxins and study the cumulative effect on organs and tissues.

**Funding:** This research was funded by ANID/FONDECYT, grant number 11181303.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.
28. Quintela, S.; Villarán, M.C.; de Armentia, I.L.; Elejalde, E. Ochratoxin A removal in wine: A review. *Food control* **2013**, *30*, 439–445. [CrossRef]

29. Moruno, E.G.; Sanlorenzo, C.; Bocaccino, B.; Di Stefano, R. Treatment with yeast to reduce the concentration of ochratoxin A in red wine. *Am. J. Enol. Vitic.* **2005**, *56*, 73–76.

30. Fernandes, A.; Venâncio, A.; Moura, F.; Garrido, J.; Cerdeira, A. Fate of ochratoxin A during a vinification trial. *Asp. Appl. Biol.* **2003**, *68*, 73–80.

31. Gambuttì, A.; Strollo, D.; Genovese, A.; Ugliano, M.; Ritienni, A.; Moio, L. Influence of enological practices on ochratoxin A concentration in wine. *Am. J. Enol. Vitic.* **2005**, *56*, 155–162.

32. Leong, S.-L.L.; Hocking, A.D.; Varelis, P.; Giannikopoulos, G.; Scott, E.S. Fate of ochratoxin A during vinification of Semillon and Shiraz grapes. *J. Agric. Food Chem.* **2006**, *54*, 6460–6464. [CrossRef]

33. Zimmerli, B.; Dick, R. Ochratoxin A in table wine and grape-juice: Occurrence and risk assessment. *Food Addit. Contam.* **1996**, *13*, 655–668. [CrossRef]

34. Silva, L.J.; Rodrigues, A.P.; Pereira, A.M.; Lino, C.M.; Pena, A. Ochratoxin A in the Portuguese Wine Market, Occurrence and Risk Assessment. *Food Addit. Contam. Part. B* **2019**, *12*, 145–149. [CrossRef]

35. Torović, L.; Lakatoš, I.; Majkić, T.; Beara, I. Risk to public health related to the presence of ochratoxin A in wines from Fruška Gora. *LWT* **2020**, *129*, 105937. [CrossRef]

36. Remiro, R.; González-Perías, E.; Lizarraga, E.; de Cerain, A.L. Quantification of ochratoxin A and five analogs in Navarra red wines. *Food Control* **2012**, *23*, 139–145. [CrossRef]

37. Pizzutti, I.R.; de Kok, A.; Scholten, J.; Righi, L.W.; Cardoso, C.D.; Rohers, G.N.; da Silva, R.C. Development, optimization and validation of a multimethod for the determination of 36 mycotoxins in wines by liquid chromatography–tandem mass spectrometry. *Talanta* **2014**, *129*, 352–363. [CrossRef] [PubMed]

38. Osty, V.; Malíř, F.; Dolkoňová, M.; Skarková, J.; Pohlí-Leszkewicz, A.; Ruprich, J. Ochratoxin A dietary exposure of ten population groups in the Czech Republic: Comparison with data over the world. *Toxins* **2015**, *7*, 3608–3635. [CrossRef]

39. Di Stefano, V.; Pintonzo, R.; Avellone, G.; Di Fiore, A.; Monte, I.; Ogorka, A.Z.T. Determination of Aflatoxins and Ochratoxins in Sicilian Sweet Wines by High-Performance Liquid Chromatography with Fluorometric Detection and Immunoaffinity Cleanup. *Food Anal. Methods* **2015**, *8*, 569–577. [CrossRef]

40. Gentile, F.; La Torre, G.L.; Potorti, A.G.; Saitta, M.; Alfa, M.; Dugo, G. Organic wine safety: UPLC-FLD determination of Ochratoxin A in Southern Italy wines from organic farming and winemaking. *Food Control* **2016**, *59*, 20–26. [CrossRef]

41. Hajík, I.; Kowalska, A.; Piekut, A.; Cwieląg-Drabek, H. A risk assessment of dietary exposure to ochratoxin A for the Polish population. *Food Chem.* **2019**, *284*, 264–269. [CrossRef]

42. Leal, T.; Abrunhosa, L.; Domingues, L.; Venâncio, A.; Oliveira, C. BSA-based sample clean-up columns for ochratoxin A determination in wine: Method development and validation. *Food Chem.* **2019**, *300*, 125204. [CrossRef]

43. Žurga, P.; Vähäki, N.; Pasković, I.; Banović, M.; Malenica Staver, M. Occurrence of Ochratoxin A and Biogenic Amines in Croatian wines. *Toxins* **2013**, *5*, 377–387. [CrossRef]

44. Batrinou, A.; Houhoula, D.; Papageorgiou, E. Rapid detection of mycotoxins on foods and beverages with enzyme linked immunosorbent assay. *Qual. Assur. Saf. Prod. Foods* **2020**, *12*, 40–49. [CrossRef]

45. Vega, M.; Rios, G.; Von Baer, D.; Mardones, C.; Tessini, C.; Herlitz, E.; Saelzer, R.; Ruiz, M.A. Ochratoxin A occurrence in wines produced in Chile. *Food Control* **2012**, *28*, 147–150. [CrossRef]

46. Al-Tahir, F.; Banaszewski, K.; Jackson, L.; Zweigenbaum, J.; Ryu, D.; Cappozzo, J. Rapid method for the determination of multiple mycotoxins in wines and beers by LC-MS/MS using a stable isotope dilution assay. *J. Agric. Food Chem.* **2013**, *61*, 2378–2384. [CrossRef] [PubMed]

47. Mitchell, N.J.; Chen, C.; Palumbo, J.D.; Bianchini, A.; Cappozzo, J.; Stratton, J.; Ryu, D.; Wu, F. A risk assessment of dietary Ochratoxin a in the United States. *Food Chem. Toxicol.* **2017**, *100*, 265–273. [CrossRef] [PubMed]

48. Marín-Ripizo, L.; Gargantini, R.; Manzano, H.; Raba, J.; Cerutti, S. Assessment of ochratoxin A occurrence in Argentine red wines using a novel sensitive quechers-solid phase extraction approach prior to ultra high performance liquid chromatography-tandem mass spectrometry methodology. *J. Sci. Food Agric.* **2017**, *97*, 2487–2497. [CrossRef] [PubMed]

49. De Jesus, C.L.; Bartley, A.; Welch, A.Z.; Berry, J.P. High incidence and levels of Ochratoxin A in wines from sources in the United States. *Toxins* **2018**, *10*, 1. [CrossRef]

50. Arrúa, A.A.; Mendes, J.M.; Arrúa, P.; Ferreira, F.P.; Caballero, G.; Casal, C.; Kohli, M.M.; Peralta, I.; Ulke, G.; Fernández Rios, D. Occurrence of Deoxynivalenol and Ochratoxin A in Beers and Wines Commercialized in Paraguay. *Toxins* **2019**, *11*, 308. [CrossRef]

51. Tamura, M.; Takahashi, A.; Uyama, A.; Mochizuki, N. A method for multiple mycotoxin analysis in wines by solid phase extraction and multifunctional cartridge purification, and ultra-high-performance liquid chromatography coupled to tandem mass spectrometry. *Toxins* **2012**, *4*, 476–486. [CrossRef] [PubMed]

52. Zhong, Q.D.; Li, G.H.; Wang, D.B.; Shao, Y.; Li, J.G.; Xiong, Z.H.; Wu, Y.N. Exposure assessment to ochratoxin A in Chinese wine. *J. Agric. Food Chem.* **2014**, *62*, 8908–8913. [CrossRef] [PubMed]

53. Puangkhum, S.; Poapolathep, A.; Jerman, U.; Imsilp, K.; Tanhan, P.; Chokejaroenrat, C.; Poapolathep, S. Monitoring and health risk of mycotoxins in imported wines and beers consumed in Thailand. *World Mycotoxin J.* **2017**, *10*, 401–409. [CrossRef]
54. Zhang, B.; Chen, X.; Han, S.-Y.; Li, M.; Ma, T.-Z.; Sheng, W.-J.; Zhu, X. Simultaneous Analysis of 20 Mycotoxins in Grapes and Wines from Hexi Corridor Region (China): Based on a QuEChERS-UHPLC-MS/MS Method. *Molecules* 2018, 23, 1926. [CrossRef] [PubMed]

55. Lasram, S.; Oueslati, S.; Chebil, S.; Mili, A.; Ghorbel, A. Occurrence of ochratoxin A in domestic beers and wines from Tunisia by immunofinity clean-up and liquid chromatography. *Food Addit. Contam. Part. B* 2013, 6, 1–5. [CrossRef] [PubMed]

56. Prelle, A.; Spadaro, D.; Denca, A.; Garibaldi, A.; Gullino, M.L. Comparison of clean-up methods for ochratoxin A on wine, beer, roasted coffee and chilli commercialized in Italy. *Toxins* 2013, 5, 1827–1844. [CrossRef]

57. Di Stefano, V.; Avellone, G.; Pitonzo, R.; Capocchiano, V.G.; Mazza, A.; Cicero, N.; Dugo, G. Natural co-occurrence of ochratoxin A, ochratoxin B and aflatoxins in Sicilian red wines. *Food Addit. Contam. Part. A* 2015, 32, 1343–1351. [CrossRef]

58. Campone, L.; Piccinelli, A.L.; Celano, R.; Pagano, I.; Russo, M.; Rastrelli, L. Rapid and automated on-line solid phase extraction HPLC–MS/MS with peak focusing for the determination of ochratoxin A in wine samples. *Food Chem.* 2018, 244, 128–135. [CrossRef]

59. Kholová, A.; Lhotská, I.; Uhrová, A.; Špánik, I.; Machynáková, A.; Solich, P.; Šatinský, D. Determination of Ochratoxin A and Ochratoxin B in Archived Tokaj Wines (Vintage 1959–2017) Using On-Line Solid Phase Extraction Coupled to Liquid Chromatography. *Toxins* 2020, 12, 739. [CrossRef]

60. Remiro, R.; Irigoyen, A.; González-Peñas, E.; Lizarraga, E.; de Cerain, A.L. Levels of ochratoxins in Mediterranean red wines. *Food Control* 2013, 32, 63–68. [CrossRef]

61. FAO. Manual sobre la aplicación del sistema de Análisis de Peligros y de Puntos críticos de control (APPCC) en la prevención y control de las micotoxinas. *Estud. FAO Aliment. Nutr.* 2003, 73, 130.

62. Nogueira, L.; Foerster, C.; Groopman, J.; Egner, P.; Koshiol, J.; Ferreccio, C. Association of aflatoxin with gallbladder cancer in Chile. *JAMA* 2015, 313, 2075–2077. [CrossRef]

63. Pitt, J. Toxigenic fungi and mycotoxins. *Br. Med. Bull.* 2015, 16, 5987–5991. [CrossRef]

64. Castegnaro, M.; Canadas, D.; Vrabcheva, T.; Petkova-Bocharova, T.; Chernozemsky, I.N.; Pfohl-Leszkowicz, A. Balkan endemic nephropathy: Role of ochratoxins A through biomarkers. *Mol. Nutr. Food Res.* 2006, 50, 519–529. [CrossRef]

65. Pfohl-Leszkowicz, A.; Manderville, R.A. Ochratoxin A: An overview on toxicity and carcinogenicity in animals and humans. *Mol. Nutr. Food Res.* 2007, 51, 61–99. [CrossRef] [PubMed]

66. Malir, F.; Ostry, V.; Pfohl-Leszkowicz, A.; Malir, J.; Toman, J. Ochratoxin A: Molecular interactions, mechanisms of toxicity and actions at the molecular level. *Toxins* 2016, 8, 111. [CrossRef] [PubMed]

67. Malir, F.; Ostry, V.; Pfohl-Leszkowicz, A.; Malir, J.; Toman, J. Ochratoxin A: 50 Years of Research. *Toxins* 2016, 8, 191. [CrossRef] [PubMed]

68. Patel, V.B.; Preedy, V.R. *Handbook of Nutrition, Diet., and Epigenetics*; Springer International Publishing: Cham, Switzerland, 2019.

69. Berger, V.; Gabriel, A.-F.; Sergent, T.; Troutet, A.; Larondelle, Y.; Schneider, Y.-J. Interaction of ochratoxin A with human intestinal Caco-2 cells: Possible implication of a multidrug resistance-associated protein (MRP2). *Toxicol. Lett.* 2003, 140–141, 465–476. [CrossRef]

70. Il’ichev, V.V.; Perry, J.L.; Simon, J.D. Interaction of ochratoxin A with human serum albumin. Preferential binding of the diand pH effects. *J. Phys. Chem. B* 2002, 106, 452–459. [CrossRef]

71. Leitner, A.; Zöllner, P.; Paolillo, A.; Stroka, J.; Papadopoulou-Bouraoui, A.; Jaborek, S.; Anklam, E.; Lindner, W. Comparison of methods for the determination of ochratoxin A in wine. *Anal. Chim. Acta* 2002, 453, 33–41. [CrossRef]

72. Osty, V.; Malir, F.; Toman, J.; Grosse, Y. Mycotoxins as human carcinogens—The IARC Monographs classification. *Mycotoxin Res.* 2017, 33, 65–73. [CrossRef]

73. Ikoma, T.; Suchiya, Y.; Asai, T.; Okano, K.; Ito, N.; Endoh, K.; Yamamoto, M.; Nakamura, K. Ochratoxin A contamination of red chili peppers from Chile, Bolivia and Peru, countries with a high incidence of gallbladder cancer. *Asian Pac. J. Cancer Prev.* 2015, 16, 5987–5991. [CrossRef]

74. Ringot, D.; Chango, A.; Schneider, Y.-J.; Larondelle, Y. Toxicokinetics and toxicodynamics of ochratoxin A, an update. *Chem. Biol. Interact.* 2006, 159, 18–46. [CrossRef] [PubMed]

75. Fazekas, B.; Tar, A.; Kovács, M. Ochratoxin A content of urine samples of healthy humans in Hungary. *Acta Vet. Hung.* 2005, 53, 35–44. [CrossRef] [PubMed]

76. Solfrizzo, M.; Gambacorta, L.; Visconti, A. Assessment of multi-mycotoxin exposure in southern Italy by urinary mul-ti-biomarker determination. *Toxins* 2014, 6, 523–538. [CrossRef] [PubMed]

77. Heyndrickx, E.; Sioen, I.; Huybrechts, B.; Callebaut, A.; De Henauw, S.; De Saeger, S. Human biomonitoring of multiple mycotoxins in the Belgian population: Results of the BIOMYCO study. *Environ. Int.* 2015, 84, 82–89. [CrossRef]

78. Fuchs, R.; Hult, K.; Appelgren, L. Distribution of 14C-ochratoxin A and 14C-ochratoxin B in rats: A comparison based on whole-body autoradiography. *IARC Sci. Publ.* 1991, 115, 201–203.

79. Mally, A.; Keim-Heusler, H.; Amberg, A.; Kurz, M.; Zepnik, H.; Mantle, P.; Völkel, W.; Hard, G.C.; Dekant, W. Biotransformation and nephrotoxicity of ochratoxin B in rats. *Toxicol. Appl. Pharmacol.* 2005, 206, 43–53. [CrossRef]

80. Müller, G.; Burkert, B.; Rosner, H.; Köhler, H. Effects of the mycotoxin ochratoxin A and some of its metabolites on human kidney cell lines. *Toxicol. In Vitro* 2003, 17, 441–448. [CrossRef]

81. Heussner, A.H.; Bingle, L.E. Comparative ochratoxin toxicity: A review of the available data. *Toxins* 2015, 7, 4253–4282. [CrossRef]
82. Köhler, H.; Heller, M.; Erler, W.; Müller, G.; Rosner, H.; Gräfe, U. Effect of ochratoxin A and ochratoxin C on the monocyte and lymphocyte function. *Mycotoxin Res.* 2002, 18, 169–172. [CrossRef]

83. Pinelli, E.; El Adlouni, C.; Pipy, B.; Quartulli, F.; Pfohl-Leszkowicz, A. Roles of cyclooxygenase and lipoxygenases in ochratoxin A genotoxicity in human epithelial lung cells. *Environ. Toxicol. Pharmacol.* 1999, 7, 95–107. [CrossRef]

84. El Adlouni, C.; Pinelli, E.; Azémar, B.; Zaoui, D.; Beaune, P.; Pfohl-Leszkowicz, A. Phenytoin increases DNA adduct and metabolites formed by ochratoxin A: Role of CYP 2C9 and microsomal glutathione-S-transferase. *Environ. Mol. Mutagenesis* 2000, 35, 123–131. [CrossRef]

85. Commission, E. Commission Regulation (EC) No 123/2005 of 26 January 2005 amending regulation (EC) No 466/2001 as regards ochratoxin A. *Off. J. Eur. Union* 2005, 25, 3–5.

86. EFSA, (European Food Safety Authority). Scientific Opinion on the Risks to Public Health Related to the Presence of Ochratoxin A in Food. Available online: http://www.efsa.europa.eu/en/consultations/call/public-consultation-scientific-opinion-risks-public-health-related accessed on 1 March 2021.

87. Pena, A.; Cerejo, F.; Silva, L.; Lino, C. Ochratoxin A survey in Portuguese wine by LC–FD with direct injection. *Talanta* 2010, 82, 1556–1561. [CrossRef] [PubMed]

88. Quintela, S.; Villarán, M.C.; de Armentia, I.L.; Elejalde, E. Occurrence of ochratoxin A in Rioja Alavesa wines. *Food Chem.* 2011, 126, 302–305. [CrossRef]

89. Markaki, P.; Delpont-Binet, C.; Grosso, F.; Dragacci, S. Determination of ochratoxin A in red wine and vinegar by immunoaffinity high-pressure liquid chromatography. *J. Food Prot.* 2001, 64, 533–537. [CrossRef]

90. Stefanaki, I.; Foufa, E.; Tsatsou-Dritsa, A.; Dais, P. Ochratoxin A concentrations in Greek domestic wines and dried vine fruits. *Food Addit. Contam.* 2003, 20, 74–83. [CrossRef]

91. Brera, C.; Soriano, J.; Debegnach, F.; Miraglia, M. Exposure assessment to ochratoxin A from the consumption of Italian and Hungarian wines. *Microchem. J.* 2005, 79, 109–113. [CrossRef]

92. EPA (Environmental Protection Agency). Technical Support Document EPA’s 2014 National Air Toxics Assessment. Available online: https://www.epa.gov/sites/production/files/2018-09/documents/2014_nata_technical_support_document.pdf (accessed on 1 March 2021).

93. Freire, L.; Sant’Ana, A.S. Modified mycotoxins: an updated review on their formation, detection, occurrence, and toxic effects. *Food Chem. Toxicol.* 2018, 111, 189–205. [CrossRef]

94. Davis, J.A.; Gift, J.S.; Zhao, Q.J. Introduction to benchmark dose methods and U.S. EPA’s benchmark dose software (BMDS) version 2.1.1. *Toxicol. Appl. Pharmacol.* 2011, 254, 181–191. [CrossRef] [PubMed]

95. Authority EFS. EFSA/WHO International Conference with support of ILSI Europe on Risk Assessment of Compounds that are both Genotoxic and Carcinogenic. *EFSA Supporting Publ.* 2006, 3, 92E.